Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex

Journal of Psychiatric Research

Volumn 41, Issue 1-2, 2007, Pages 57-62

  Chen, Mao Liang ^a   Chen, Chia Hsiang ^a,b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Catechol O methyltransferase; Clozapine; Haloperidol; Monoamine oxidase A; Monoamine oxidase B; Olanzapine; Risperidone

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOL METHYLTRANSFERASE; CLOZAPINE; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME DEGRADATION; FRONTAL CORTEX; GENE EXPRESSION; MALE; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CATECHOL O-METHYLTRANSFERASE; CLOZAPINE; DNA PRIMERS; DNA, ANTISENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FRONTAL LOBE; GENE EXPRESSION; HALOPERIDOL; MALE; MONOAMINE OXIDASE; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; RNA, MESSENGER;

EID: 33750687225     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2005.03.005     Document Type: Article

References (27)

1. Akil M., Kolachana B.S., Rothmond D.A., Hyde T.M., Weinberger D.R., and Kleinman J.E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. Journal of Neuroscience 23 (2003) 2008-2013
2. Bray N.J., Buckland P.R., Williams N.M., Williams H.J., Norton N., Owen M.J., et al. A haplotype implicated in schizophrenia susceptibility is associated reduced COMT expression in human brain. American Journal of Human Genetics 73 (2003) 152-161
3. Brunner H.G., Nelen M., Breakefeld X.O., Ropers H.H., and Van Oost B.A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262 (1993) 578-580
4. Carlsson A., Hansson L.O., Waters N., and Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Science 1 (1997) 75-94
5. Cases O., Seif I., Grimsby J., Gaspar P., Chen K., Pournin S., et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAO A. Science 268 (1995) 1763-1766
6. Cho S., Duchemin A.-M., Neff N.H., and Hadjiconstantinou M. Tyrosine hydroxylase, aromatic l-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs. Brain Research 830 (1999) 237-245
7. Damask S.P., Bovenkerk K.A., de la Pena G., Hoversten K.M., Peters D.B., Valentine A.M., et al. Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex. Brain Research Molecular Brain Research 41 (1996) 241-249
8. DeLisi L.E., Wise C.D., Bridge T.P., Rosenblatt J.E., Wagner R.L., Morihisa J., et al. A possible neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Research 4 (1981) 95-107
9. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences USA 98 (2001) 6917-6922
10. Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., et al. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology 20 (1999) 29-34
11. Fang J., Yu P.H., Gorrod J.W., and Boulton A.A. Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology 118 (1995) 206-212
12. Frederick J.A., and Meador-Woodruff J.H. Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain. Schizophrenia Research 38 (1999) 7-12
13. Hyman S.E., and Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry 153 (1996) 151-162
14. Ichikawa J., and Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotics drugs. European Archives of Psychiatry and Clinical Neuroscience 249 Suppl. 4 (1999) 90-98
15. Kusumi I., Takahashi Y., Suzuki K., Kameda K., and Koyama T. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. Journal of Neural Transmission 107 (2000) 295-302
16. Matsumoto M., Weickert C.S., Beltaifa S., Kolachana B., Chen J., Hyde T.M., et al. Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 28 (2003) 1521-1530
17. McCoy L., Cox C., and Richfield E.K. Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. European Journal of Pharmacology 318 (1996) 41-45
18. Murphy K.C., Jones L.A., and Owen M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Archives of General Psychiatry 56 (1999) 940-945
19. Shifman S., Bronstein M., Sternfeld M., Pisante-Shalom A., Lev-Lehrman E., Weizman A., et al. A highly significant association between a COMT haplotype and schizophrenia. American Journal of Human Genetics 71 (2002) 1296-1302
20. Shih J.C., Chen K., and Ridd M.J. Monoamine oxidase: from gene to behavior. Annual Review of Neuroscience 22 (1999) 197-217
21. Tejedor-Real P., Faucon Biguet N., Duman S., and Mallet J. Tyrosine hydroxylase mRNA and protein are down-regulated by chronic clozapine in both the mesocorticolimbic and the nigrostriatal systems. Neuroscience Research 72 (2003) 105-115
22. Tenhunen J., Salminen M., Lundstrom K., Kiviluoto T., Savolainen R., and Ulmanen I. Genomic organization of the human catechol-O-methyltransferase gene and its expression from two distinct promoters. European Journal of Biochemistry 223 (1994) 1049-1054
23. Timmerman W., Heijmen M., Westerink B.H., Bruggeman R., and den Boer J.A. Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain. Psychopharmacology (Berl) 144 (1999) 286-294
24. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3 (2002) 00341-003411 research
25. Van Der Krogt J.A., Van Valkenburg C.F.M., and Belfroid R.D.M. Rat brain monoamine oxidase activity is not affected by repeated administration of haloperidol. Journal of Pharmacy and Pharmacology 34 (1982) 529-531
26. Weickert T.W., Goldberg T.E., Marenco S., Bigrlow L.B., Egan M.F., and Weinberger D.R. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 28 (2003) 1491-1500
27. Wyatt R.J., Murphy D.L., Belmaker R., Cohen S., Donnelly C.H., and Pollin W. Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science 179 (1973) 916-918